- Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel treatments for inflammatory lung diseases and cancer
- Cantex is led by Stephen Marcus, M.D., and Neil Flanzraich, seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience
READ MORE
- Current lead product, Dicopp®, targets inflammasome-driven complications of COVID-19 infection, pulmonary inflammatory diseases, and cancer
- DSTAT, licensed to Chimerix, Inc. (NASDAQ: CMRX), is in advanced stage clinical trials for acute myeloid leukemia and COVID-19 associated acute lung injury
READ MORE
April 2020 – Chimerix, Exclusive Licensee of Cantex’ Lead Product DSTAT, has Announced Initiation of a Phase 2/3 Study of DSTAT, Formerly Known as CX-01, in Acute Lung Injury for Patients with Severe COVID-19.
READ MORE
July 2019 – Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid Leukemia.
READ MORE
DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML)
LEARN MORE